SHANGHAI JUNSHI BIOSCIENCES CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.41 HKD | -2.49% |
|
-9.92% | -51.44% |
| Sales 2024 * | 1.83B 253M 1.98B | Sales 2025 * | 3.18B 439M 3.43B | Capitalization | 21.05B 2.91B 22.76B |
|---|---|---|---|---|---|
| Net income 2024 * | -1.89B -261M -2.04B | Net income 2025 * | -808M -112M -874M | EV / Sales 2024 * | 10.1 x |
| Net cash position 2024 * | 2.6B 359M 2.81B | Net cash position 2025 * | 1.67B 230M 1.8B | EV / Sales 2025 * | 6.1 x |
| P/E ratio 2024 * |
-5.13
x | P/E ratio 2025 * |
-8.71
x | Employees | 2,568 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Shanghai Junshi Biosciences Co., Ltd.
More press releases
More news
| 1 day | -2.18% | ||
| 1 week | -9.92% | ||
| Current month | -4.36% | ||
| 1 month | -10.78% | ||
| 3 months | -36.73% | ||
| 6 months | -46.42% | ||
| Current year | -51.44% |
1 week
9.41
10.56
1 month
9.4111.44
Current year
9.4119.60
1 year
9.4133.70
3 years
9.4187.60
5 years
9.4197.15
10 years
9.4197.15
| Managers | Title | Age | Since |
|---|---|---|---|
Zhuo Bing Zhang
FOU | Founder | 57 | 12-12-26 |
Jianjun Zou
CEO | Chief Executive Officer | 52 | 22-04-19 |
Cong Li
CEO | Chief Executive Officer | 60 | 16-12-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roy Herbst
BRD | Director/Board Member | 60 | 18-06-23 |
Cong Li
CEO | Chief Executive Officer | 60 | 16-12-21 |
Yi Tang
BRD | Director/Board Member | 56 | 15-05-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.31% | 4 M€ | -27.92% | ||
| 0.01% | 117 M€ | -1.38% | - | |
| 0.00% | 31 M€ | +1.33% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 9.41 | -2.49% | 290 200 |
| 24-04-18 | 9.65 | -0.62% | 525,266 |
| 24-04-17 | 9.71 | 0.00% | 792,200 |
| 24-04-16 | 9.71 | -5.73% | 938,890 |
| 24-04-15 | 10.3 | -1.72% | 559,304 |
Delayed Quote Hong Kong S.E., April 18, 2024 at 10:39 pm EDT
More quotes
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company develops innovative drugs and provides clinical research commercialization services worldwide. The Company mainly provides its products in the treatment of tumor immunotherapy, metabolic diseases, inflammation or autoimmune diseases, as well as nervous system diseases. The Company's products are mainly used to treat melanoma, nasopharyngeal cancer, esophageal cancer, urothelial cancer, malignant lymphoma and others. The Company provides its products for domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.92
CNY
Average target price
22.5
CNY
Spread / Average Target
+152.26%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -51.44% | 2.93B | |
| -6.82% | 84.57B | |
| +3.95% | 39.93B | |
| -26.37% | 27.93B | |
| +52.09% | 24.21B | |
| -6.59% | 17.17B | |
| -32.37% | 13.93B | |
| -10.45% | 12.3B | |
| -15.88% | 11.84B | |
| -2.85% | 7.91B |
- Stock Market
- Equities
- 1877 Stock
